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Abstract
In the formulation of nanoparticles, poly(lactic-co-glycolic acid) (PLGA) is commonly employed due to its Food and Drug
Administration and European Medicines Agency approval for human use, its ability to encapsulate a variety of moieties, its
biocompatibility and biodegradability and its ability to offer a range of controlled release profiles. Common methods for the
production of PLGA particles often adopt harsh solvents, surfactants/stabilisers and in general are multi-step and time-consuming
processes. This limits the translation of these drug delivery systems from bench to bedside. To address this, we have applied
microfluidic processes to develop a scale-independent platform for the manufacture, purification andmonitoring of nanoparticles.
Thereby, the influence of various microfluidic parameters on the physicochemical characteristics of the empty and the protein-
loaded PLGA particles was evaluated in combination with the copolymer employed (PLGA 85:15, 75:25 or 50:50) and the type
of protein loaded. Using this rapid production process, emulsifying/stabilising agents (such as polyvinyl alcohol) are not required.
We also incorporate in-line purification systems and at-line particle size monitoring. Our results demonstrate the microfluidic
control parameters that can be adopted to control particle size and the impact of PLGA copolymer type on the characteristics of
the produced particles. With these nanoparticles, protein encapsulation efficiency varies from 8 to 50% and is controlled by the
copolymer of choice and the production parameters employed; higher flow rates, combined with medium flow rate ratios (3:1),
should be adopted to promote higher protein loading (% wt/wt). In conclusion, herein, we outline the process controls for the
fabrication of PLGA polymeric nanoparticles incorporating proteins in a rapid and scalable manufacturing process.
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Introduction
Poly(lactic-co-glycolic acid) (PLGA) is a polyester, which
degrades by hydrolysis of the ester connections into its
monomer components lactic (PLA) and glycolic acid
(PGA) and is commonly used in the production of nano-
particles that are investigated for the delivery of drugs and
vacc ine an t igens . These nanopa r t i c l e s can be
manufactured through a wide range of methods, and the
physicochemical properties (size, morphology, surface
charge) can be easily manipulated in order to promote
appropriate biological activity e.g. [1–3]. When selecting
which PLGA to be used within nanoparticles, the mono-
mer molar ratio, the average molecular weight, the degree
of crystallinity, the size and shape of monomer are all
important. The main PLGA copolymers used in research
are 50:50, 65:35, 75:25 and 85:15 (PLA:PGA ratio).
Varying the percentage of PLA or PGA present in the
polymer composition influences the hydrophilicity of the
polymer and thus the polymer degradation rate and release
rate of the entrapped moiety [4–6]. Therefore, PLGA co-
polymers with higher PGA content show accelerated deg-
radation when compared to PLGA copolymers with
higher PLA content.
When considering the manufacturing process adopted for
the production of nanoparticles, both the particle attributes and
the complexity of the process are considerations. With many
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of the current manufacturing methods, scale up is difficult and
requires large amounts of solvents. In contrast, microfluidics
manipulates the mixing of liquid flows in microsized channels
and allows the formation of size-controlled nanoparticles [7].
Advantages of using microfluidics include the opportunity for
continuous operation, easy control, high efficiency and low
cost, making it an attractive alternative compared to other
traditional manufacturing methods [7]. Microfluidics also of-
fers the potential for scale-independent manufacture, which
offers additional economic advantages including tailored pro-
duction scales and smaller facility footprint, which converts
into reduce cost of goods. These combined advantages allow
for rapid translation from bench to bedside for new polymeric
nanoparticle formulations, thereby de-risking their adopting as
nanomedicines.
In our laboratories, we have been working with the stag-
gered herringbone micromixer (SHM) in combination with
the Nanoassemblr® from Precision Nanosystems Inc.
(Vancouver, Canada) for the production of liposomes [8, 9].
Previous studies have demonstrated the formulation of poly-
meric nanoparticles using microfluidics to incorporate small
drugs molecules (e.g. [10, 11]) or different types or RNA (e.g.
[12]). However, knowledge of the application of microfluidics
to produce protein-loaded nanoparticles is lacking.
Furthermore, to advance the progress of microfluidic produc-
tion, we have also incorporated in-line purification methods
and at-line particle size monitoring as part of a continuous
manufacturing process. Therefore, the aim of this study was
to investigate, develop and define a microfluidic process for
the production of protein-loaded PLGA nanoparticles that in-
corporate purification and process monitoring in a rapid and
scalable manner.
Materials and methods
Materials
For the preparation of the delivery systems, polymers PLGA
85:15 (Mw: 50,000-75,000), 75:25 (Mw: 66,000-107,000)
and 50:50 (Mw: 30,000-60,000) from Sigma-Aldrich were
used. Sodium hydroxide (NaOH), polyvinyl alcohol (PVA
Mw: 31,000), ovalbumin (OVA) and bovine serum albumin
(BSA) were purchased from Sigma-Aldrich Company Ltd.,
Poole, UK. The tuberculosis vaccine candidate ‘Hybrid 56’
(H56) was donated by Statens Serum Institut (SSI),
Copenhagen, Denmark. 2-Amino-2-(hydroxymethyl)-1,3-
propanediol (Tris) was obtained from ICN Biomedicals Inc.
(Aurora, OH, USA) and prepared at a 10 mM concentration
and pH 7.4 unless otherwise stated. Acetonitrile (ACN),
trifluoroacetic acid (TFA) and all other reagents were of ana-
lytical grade and purchased from commercial suppliers.
Manufacturing of poly(lactic-co-glycolic acid)
nanoparticles using microfluidics
PLGA nanoparticles were manufactured by the microfluidics
method using the Nanoassemblr® Benchtop (Precision
Nanosystems Inc., Vancouver, Canada). Briefly, polymer (ei-
ther PLGA 85:15, 75:25 or 50:50) was dissolved in ACN at a
concentration of 10 mg/mL (1% w/v). For the production of
empty nanoparticles, Tris buffer was used as aqueous phase,
whereas for protein-loaded nanoparticles, protein (OVA, BSA
or H56) was loaded in the aqueous phase at the desired con-
centration (0.2, 0.5 or 1 mg/mL). The addition of PVA at
different concentrations (0, 0.5, 1 and 2% w/v) into the aque-
ous phase during the production of PLGA nanoparticles was
also tested. In order to evaluate the impact of the different
production parameters, total flow rates (TFRs) 5, 10 and
15 mL/min and flow rate ratios (FRR) 1:1, 3:1 and 5:1 were
selected. Encapsulation efficiencies (EE%) were calculated as
a percentage of the initial protein concentration × the dilution
factor from each FRR. Loading capacity (% wt/wt) was cal-
culated as percentage of the mass of protein loaded into the
nanoparticles divided by the mass of the whole nanoparticle.
Characterisation of the PLGA particle size, zeta
potential and morphology
The particle size and zeta potential of the polymer nanoparti-
cles were determined by dynamic light scattering (DLS) using
a Malvern nano ZS (Malvern PANalytical, Worcestershire,
UK). Three measurements at 25 °C were conducted on the
samples, which were previously diluted in filtered Tris buffer
(10 mM, pH 7.4) to achieve the optimal particle concentration
(0.25 mg/mL) with the optimum attenuator number (att. 6–7).
To prove the applicability of the microfluidics method for
continuous manufacturing, an AT-line Malvern sizer was used
to measure the PLGA nanoparticles. The system was run at
the following: 0.5 mL/min sample flow rate, 10 mL/min dil-
uent flow rate and 90 s delay time between measurements. To
consider morphology, scanning electron microscopy
(SEM) was used to visualise the polymer nanoparticles.
These were fixed and air dried onto a metal stub and then
coated with gold and observed under the microscope. This
procedure was carried out by David McCarthy from
DMmicroscopy. Images were taken on a FEI Quanta FEG,
Eindhoven, the Netherlands. The voltage used is shown at
the foot of each image, usually 5 or 8 KV.
Purification of the PLGA nanoparticles: solvent
removal and non-encapsulated antigen
For the removal of the solvent used for the dissolution of the
polymer and preparation of nanoparticles, samples were in a
dialysis tubing (Mw = 12,000–14,000 Da, Sigma-Aldrich
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Company Ltd., Poole, UK) against Tris buffer for an hour.
PLGA nanoparticles were then purified via tangential flow
filtration (KR2i TFF System®, SpectrumLabs, USA) at
27 mL/min and 12 diafiltration volumes in order to remove
unbound protein. The TFF column used for this purpose was a
750-kDa modified polyethersulfone (mPES) column. Dialysis
was carried out before TFF due to the incompatibility of the
column with the ACN used for the preparation of the
nanoparticles.
Quantification of protein loading and polymer
recovery
Quantification of the protein loading within the PLGA nanopar-
ticles was performed by reverse phase HPLC (RP-HPLC) using
a UV detector. Jupiter 5 μ C18(2) column (Phenomenex) pore
size 300 Å was used as stationary phase. For the preparation of
the samples, proteins and/or protein-loaded nanoparticles were
dissolved in 0.1 M NaOH/Tris buffer (1:1 v/v) and heated up for
approx. 1.5–2 h in a water bath at 35 °C. A gradient elution
method containing 90% H2O, 10% ACN and 0.1% TFA in
one phase (mobile phase A) and 70% acetonitrile, 30% H2O
and 0.1% TFA in the other phase (mobile phase B) was followed
[13, 14]. Injection volume was 50 μL, flow rate 1 mL/min, UV
wavelength 210 nm, column temperature either 25 °C (OVA and
BSA) or 60 °C (H56), and the total duration of the run was
20 min.
Quantification of the polymer recovery was performed by
HPLC using an ELSD detector based on the method devel-
oped by Riehl et al. [15]. Luna 5 μ C18(2) column
(Phenomenex) pore size of 100 Å was used. HPLC-ELSD
settings were kept constant as follows: 30μL injection volume
in a partial loopfill injection mode, 100 μL loop volume and
15 μL tubing volume. Column temperature was maintained at
35 °C, whereas the ELSD temperature was set at 52 °C in all
the runs. Nitrogen was used as a carrier gas at 3.5 bar inlet
pressure. Clarity DataApex version 4.0.3.876 was used for
data analysis.
Statistical analysis
One-way ANOVA and two-way ANOVA followed by
Tukey’s multiple comparison test were used for the data anal-
ysis. All the experiments were carried out at least in triplicate
unless otherwise stated. Results are the mean of at least 3
measurements ± standard deviation (SD) which is plotted as
error bars.
Results and discussion
In the development of nanoparticles, the size and size distri-
bution or uniformity, i.e. polydispersity index (PDI), are
essential characteristics. Low PDIs are difficult to obtain in
some formulations depending on the nature of the compounds
used and the manufacturing techniques applied. However, it is
necessary to have a narrow range of particle sizes within the
samples since a broad range may have different pharmacoki-
netic profiles; affect cell uptake; and in the role of adjuvants, it
can influence their immunogenic properties [16–19].
Similarly the zeta potential can give insights into the surface
charge of the particles which can impact on their biological
activity [20]. Therefore, our initial studies focused on the ef-
fect of microfluidic parameters in combination with PLGA
copolymer ratio (50:50; 75:25; 85:15) on the size, PDI and
zeta potential of our PLGA particles.
Microfluidics manufacturing of PLGA nanoparticles:
The effect of process parameters
To get an overview of the impact that microfluidic parameters
have on the mean particle size, PDI and zeta potential of the
PLGA nanoparticles, the TFR and the FRR were varied and
assessed (Fig. 1). TFR was set at 3 different speeds: 5, 10 and
15 mL/min and, for each speed, three aqueous:organic phase
(buffer:ACN) ratios (FRR) were used: 1:1, 3:1 and 5:1. The
initial PLGA concentration in ACN was 10 mg/mL (1% w/v)
for all the formulations prepared. Higher (12.5 mg/mL) and
lower (7.5 mg/mL) concentrations were also tested and the
results did not differ significantly from each other (data not
shown), and thus, the concentration was fixed at 10 mg/mL
for all the studies carried out.
PLGA nanoparticles produced using the copolymer 50:50
showed the smallest particle sizes among the three PLGA copol-
ymers studied, ranging from 94 to 150 nm, with the particle size
reducing as the production speed increased from 5 to 15 mL/min
(Fig. 1). However, for copolymers 75:25 and 85:15, there was no
notable difference in particle size across the production speeds
tested at each of the three FRRs tested (FRR1:1, 3:1 and 5:1; Fig.
1a, b and c respectively). In contrast, varying the FRRwas shown
to have a significant (p < 0.05) impact on the colloid size with
particles decreasing in size for all three copolymerswhen increas-
ing the aqueous to organic phase ratio from 1:1 to 5:1 (Fig. 1a, b
and c, respectively). This trend was observed with all three poly-
mer ratios tested and became more notable with increasing poly-
mer ratio (Fig. 1). In general, across the formulations, the PDI
values were ≤ 0.2, and samples had similar morphology when
viewed via SEM (Fig. 1e–g). Regarding zeta potential, all three
copolymers produced were highly anionic (Fig. 1d). No signifi-
cant differences were observed between the different
microfluidic parameters applied. In general, PLGA 50:50 pro-
duced particles with ~− 40 mV at all FRRs and TFRs tested.
Particles prepared using PLGA 85:15 produced particles with
~ − 50 mV, and PLGA 75:25 produced the most anionic parti-
cles, with a zeta potential of approximately ~− 60 mV.
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Based on these studies, it can be seen that in terms of size,
both TFR and FRR can be considered as critical process param-
eters, most notably for PLGA 50:50 formulations. However, in
the case of the more hydrophobic polymers, the TFR does not
have a notable impact. Neither the TFR nor the FRR influence
the zeta potential as would be expected given this is dictated by
the polymer used. The negative zeta potential is attributed to
PLGA preparations due to carboxyl groups present in their
structure. Shabir et al. hypothesised that the particle size of the
PLGA nanoparticles could influence on the zeta potential due to
the reduction of COO− groups available on the surface of the
smaller particles and, subsequently, increasing the zeta potential
[21]. Chiesa et al. also showed the same trend on PLGA
nanoparticles produced using this micromixer system [10]. It
has been proposed that FRR impacts on the nanoparticle
formation due to the increase in the polarity within the
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Fig. 1 Optimisation of the
process parameters for the
production of polymeric
nanoparticles using microfluidics.
Polymeric nanoparticles were
prepared by microfluidics, and
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characteristics (particle size (bars)
and PDI (dots)) at a FRR 1:1, b
FRR 3:1 and c FRR 5:1 were
measured. The effect of FRR on d
zeta potential was also measured.
Results represent the mean ± SD
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microfluidics cartridge and therefore the different solvent phase
concentration [8, 22]. However, it is important to note that the
intrinsic factors of the PLGA copolymer also dictate the
physicochemical characteristics of the resulting nanoparticles
with higher PLA content increasing the particle size
irrespective of the process parameters employed. This might a
combination of the higher hydrophobicity of the polymer and the
manufacturing method, since the polarity during nanoparticle
formation is reduced and, thus, larger particles are produced.
The effect of the addition of a stabiliser into the PLGA
nanoparticles
The effect of incorporating surfactants/stabilisers into the
PLGA nanoparticles formulated using microfluidics was
also investigated. PVA is a non-ionic surfactant, which is
one of the most common stabilisers used during the emul-
sification method for the preparation of PLGA particles.
PVA favours the emulsification process and avoids the
aggregation of PLGA droplets [23]. For this reason, dif-
ferent amounts of PVA were incorporated into the formu-
lations to consider if this enhanced particle formation and/
or stability [24–27]. Due to the high hydrophilicity of this
polymer, PVA was added into the aqueous phase (Tris
buffer pH 7.4, 10 mM) and the stability (at 4 °C) of the
particles in terms of size was measured over time (Fig. 2).
Incorporation of PVA produced larger particle sizes, in-
creasing the particle size from approximately 230 to 310 nm
with the addition of 2% PVA but did not significantly influ-
ence the PDIs, with all formulations having a 0.2 or below,
which is representative of a homogeneous particle size popu-
lation (Fig. 2a). The zeta potential of the PLGA nanoparticles
changed from highly anionic to neutral upon addition of PVA
in the formulations (Fig. 2b). However, irrespective of the
PVA content, all four formulations (no PVA, 0.5% PVA, 1%
PVA and 2% PVA) were stable over the period of the study,
demonstrating that there is no need for the incorporation of the
emulsifier when polymeric nanoparticles are produced via
microfluidics (Fig. 2c, d).
The increase in particle size with the addition of PVA has
been reported in other studies. For example, Chiesa et al. added
the same concentrations of PVA into PLGA75:25 nanoparticles
manufactured throughmicrofluidics and showed that increasing
PVA concentration resulted in increased nanoparticle size from
approximately 200 to 500 nm and lower PDIs. The measured
zeta potential was also reduced upon incorporation of PVA
[10]. Kumar et al. also investigated the loading of insulin in
PLGA 50:50 and 75:25 nanoparticles and demonstrated that
addition of stabilisers into the formulation increased the particle
size [28]. In contrast, other reported work using the water-in-
oil-in-water (w/o/w) emulsion for the production of nanoparti-
cles showed that increasing surfactant concentration produces
smaller particles and the lack of stabiliser increases the particle
size [29]. This may be due to the emulsifier being added to
stabilise the emulsion during the formation of the nanoparticles.
However, in the case of microfluidics, the nanoparticles are
formed rapidly due to nanoprecipitation, thereby circumventing
the need for additional stabilisers such as PVA. Indeed, such
stabilisers may undermine the nanoprecipitation process and
Chiesa et al. hypothesised that an increased viscosity due to
incorporation of PVA into the microfluidics systems might de-
crease the mixing speed and, therefore, favour the formation of
larger particles [10].
Scale-independent manufacturing of nanoparticles:
yield, purification and AT-line particle size monitoring
The manufacture of nanoparticles should be scalable in order to
succeed as a product for commercial use, and continuous and/or
scale-independent processing offers several advantages over
batch processing. For example, microfluidics, which is consid-
ered a scale-independent method for the manufacture of nano-
particles, can produce scalable volumes as determined by the run
time. In contrast, batch processing is restricted by the size of the
instrument used for the manufacture. For the purification of
nanoparticles dialysis, centrifugation or gel filtration are com-
monly used within the laboratory setting; however, these
methods are time consuming and difficult to scale up. Thus, cross
flow filtration or tangential flow filtration (TFF) can be used for
the removal of non-entrapped drug/protein from the nanoparticle
suspensions. Therefore, to consider a manufacturing process
which incorporates TFF purification and particle sizemonitoring,
we assessed polymer recovery, particle size attributes and nano-
particle recovery after manufacture and TFF purification using
nanoparticles prepared fromPLGA50:50, 75:25 and 85:15with-
out the addition of protein (Fig. 3).
With all three polymers, recovery was between 40 and 80%
depending on the polymer and FRR used (Fig. 3a). The recovery
of the PLGA 85:15 was significantly (p < 0.05) lower compared
to the other PLGAs; the polymer content for 85:15 PLGA nano-
particles prepared at FRR 1:1 was 56 ± 4%whereas for FRR 3:1
and 5:1 the polymer content was 41 ± 4% and 49 ± 1% respec-
tively (Fig. 3a). PLGA nanoparticles of 75:25 monomer ratio
showed 79 ± 5%, 71 ± 6% and 63 ± 1% recovery for formula-
tions prepared at FRR 1:1, 3:1 and 5:1 respectively (Fig. 3a).
Regarding PLGA 50:50 formulations, the recovery was up to
64 ± 1%, 72 ± 5% and 72 ± 4% at FRR 1:1, 3:1 and 5:1, respec-
tively. The high PLA ratio may be related to higher hydropho-
bicity and polymer precipitation within the cartridge [2]. Despite
the lower polymer recovered observed compared to the high
(˜ 100%) lipid recovery obtained after liposome manufacture
using microfluidics showed previously [30], the values are in-
line with those reported in the literature. Values between 40 and
80% are commonly reported when other techniques such as the
double emulsion method (w/o/w), spray-drying or
nanoprecipitation have been applied for the manufacture of
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polymers [31, 32]. In terms of particle attributes after purification,
measurement of the particle size and size distribution after TFF
demonstrated that neither the size of the particles, nor the PDI
significantly changed after purification for all three PLGA nano-
particle formulations tested (Fig. 3b). Nanoparticle yield after
purification was also high; all three copolymers showed a recov-
ery over 90% (Fig. 3b).
The development of analytical methods which provide better
information and control of the manufacturing process is required
in particular in the case of nanomedicines, where size is a key
critical quality attribute. The size of the particulate delivery sys-
tems can be measured by a wide range of techniques such as
DLS, microscopy and particle tracking. Many of these tech-
niques are only available for off-line measurements and cannot
be applied for continuous processing. Real-time particle size
analysis can be performed during continuous processing thus,
any problem arising during production can be detected and
corrected. The results in Fig. 3c show the addition of at-line
particle size monitoring to the manufacturing process. The
PLGA nanoparticles formulated using microfluidics at a selected
TFR 10 mL/min and FRR 1:1 were sized using both an off-line
system and an at-line system (real-time measurement). Results
show the possibility to combine microfluidic fabrication, TFF
purification and at-line particle size monitoring for PLGA
nanoparticles.
The effect of the microfluidic process parameters
on the physicochemical characteristics and loading
efficiencies of the PLGA nanoparticles
Within our work, we are interested in the development of
PLGA nanoparticles as vaccine adjuvants therefore the man-
ufacture of PLGA nanoparticles encapsulating a model anti-
gen (OVA) was carried out using microfluidics. OVA is a well
characterised and established protein with a molecular weight
of ~ 45 kDa. Therefore, for the optimisation of the
microfluidic parameters and the study of their influence in
the protein loading, OVA was loaded in-line in a single step
process by adding it in the aqueous phase. PLGA nanoparti-
cles were prepared by altering the process parameters of the
microfluidic system.
The effect of the process parameters on protein-loaded PLGA
nanoparticles
To develop protocols for incorporation of protein within the
nanoparticles, the effect of the FRRs (1:1, 3:1 and 5:1) was
evaluated on the PLGA 85:15, 75:25 and 50:50 copolymers
loaded with a fixed initial amount of OVA and prepared at a
fixed TFR of 10mL/min (Fig. 4). Figure 4 a shows the particle
size and PDI of the nanoparticles incorporating protein, which
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follows the same trend observed for the empty counterparts
(Fig. 1); increasing FRR resulted in a decreased particle size,
whereas this parameter did not affect the PDI. The copolymer
50:50 showed smallest sizes (below 115 nm) followed by
copolymers 75:25 and 85:15. All the PDIs were below 0.3
in all the cases. However, the addition of 0.2 mg/mL protein
increased (up to 30%) the size of some PLGA nanoparticles
when compared to the ‘empty’ ones (Fig. 1 vs Fig. 4). In terms
of their zeta potential, all three copolymers resulted in highly
anionic nanoparticles as expected from PLGA-based systems
with values from − 34 to − 55 mV (Fig. 4b) and no significant
differences were observed between empty and loaded
nanoparticles.
Figure 4 c shows the impact of the FRR on the per-
centage encapsulation efficiency (EE%) and loading ca-
pacity (% wt/wt) of PLGA nanoparticles at 0.2 mg/mL
initial protein concentration. In general, increasing the
FRR reduces the EE% with the FRR 5:1 tending to show
the lowest antigen encapsulation with approximately 20–
30% encapsulation of the initial amount loaded irrespec-
tive of the polymer used (Fig. 4c). This may be explained
by the lower polymer concentration within the formula-
tion as the initial polymer concentration was fixed at
10 mg/mL; therefore, when PLGA nanoparticles are pro-
duced at FRR 1:1, 50% of the initial amount will be in the
final formulation. In the case of FRR 3:1 and FRR 5:1,
the polymer content is reduced down to 25% and 16.7%
respectively in the final suspension. To consider this, the
results were also plotted as % wt/wt. When the ratio of
protein loaded in relation to nanoparticle weight is con-
sidered, the loading tends to be lower at FRR 1:1 for all
three polymers compared to 3:1 and 5:1 which gives sim-
ilar loading (Fig. 4c). With all 3 polymers, the protein-
loaded nanoparticles were spherical in nature and the par-
ticle size is seen to increase with increasing PLA:PGA
ratio (Fig. 4d–f).
The influence of the copolymer ratio has been reported
by Cao et al. [33]; when comparing PLGA 50:50 and PLGA
85:15 microparticles encapsulating OVA, PLGA 85:15 en-
capsulated approximately 24%, whereas the copolymer
50:50 only encapsulated ~ 15% [33]. Mukherjee et al. also
showed that the higher hydrophobicity of PLGA 85:15 re-
sulted in high protein loading compared to particles pro-
duced using PLGA 50:50 (38% vs 10% respectively) [34].
Similarly, De Rosa et al. produced PLGA microparticles
using copolymers 50:50 and 75:25 and, again, the higher
hydrophobicity and viscosity of the PLGA 75:25 resulted
in higher EE% compared to PLGA 50:50 microparticles
[35]. In terms of the microfluidic production, the use of
PLGA with a higher hydrophobic content may promote
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Fig. 3 An overview of the process parameters measured during the
production process of PLGA nanoparticles. a Manufacture—polymer
recovery after manufacture of the PLGA 50:50, 75:25 and 85:15 nano-
particles formulated using microfluidics (MF) at TFR 10 mL/min and
FRR 1:1, 3:1 and 5:1. b Purification via TFF—physicochemical charac-
teristics before (MF) and after purification (TFF) and recovery of the
polymeric nanoparticles (FRR 1:1, TFR 10 mL/min). c Monitoring—
the particle size was monitored with Malvern OFF-line and AT-line in
order to demonstrate the capability of the microfluidics method for con-
tinuous manufacturing of PLGA nanoparticles (particle sizes and inten-
sity graphs for PLGA nanoparticles produced at FRR 1:1 and TFR
10 mL/min). For this study, nanoparticles without loaded protein were
studied
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more rapid aggregation and nanoparticle formation and thus
capturing higher amounts of proteins. This may also explain
why when high solvent levels are used; protein loading is
lower as the higher solvent concentration will slow down
nanoparticle formation.
After testing the FRR, the next step was to investigate the
effect of the TFR in the formulation of these antigen loaded
PLGA nanoparticles. In this case, the FRR was fixed at 1:1,
whereas the TFR varied from 5 to 15 mL/min (Fig. 5). In
terms of size, PDI and zeta potential, values were similar to
those of ‘empty’ nanoparticles, with TFR having neither
notable effect on size and PDI (Fig. 5a) nor zeta potential
(Fig. 5b). Regarding protein encapsulation and loading ca-
pacity (Fig. 5c–e), again TFR made no notable impact.
These results demonstrate higher processing speeds can be
used for the production of polymeric PLGA nanoparticles
and that the FRR and the polymer selection are the two key
parameters dictating protein loading.
The effect of the initial antigen concentration loaded
in the physicochemical characteristics
and encapsulation efficiency of the PLGA
nanoparticles
To consider the impact of varying OVA dose, different initial
OVA concentrations (0.2, 0.5 and 1 mg/mL) were loaded in-
line with the microfluidics system at a selected TFR of 10 mL/
min and FRR 1:1 (0.1, 0.25 and 0.5 mg/mL OVA final con-
centrations after microfluidics respectively). Physicochemical
characteristics of the formulations are shown in Fig. 6. The
size of the particles notably increased for PLGA 85:15 nano-
particles from 300 to 800 nm (Fig. 6a). In contrast, PLGA
75:25 nanoparticles showed only small changes in size (from
240 to 300 nm), and PLGA 50:50 nanoparticles remained
approximately the same (112 to 130 nm). All the nanoparticles
were highly anionic, and no significant differences were found
in terms of their zeta potential (results not shown).
In terms of varying the initial antigen concentration, the
dominant factor in EE% is the polymer selection (Fig.
6b, c); EE% in PLGA 50:50 nanoparticles was approximately
20% irrespective of the initial protein concentration tested
whilst PLGA 75:25 and 85:15 showed higher EE% (approx.
40–60%; Fig. 6b), suggesting that the nanoparticles have a
wide range of entrapment capacity. In terms of % wt/wt load-
ing, increasing the initial protein loading translated into high
total loading within the particles and higher loading may be
-80
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Fig. 5 The effect of the TFR on the physicochemical characteristics of
OVA loaded PLGA nanoparticles (FRR 1:1): a particle size (bars) and
particle size distributions (dots) and b zeta potential. Encapsulation
efficiency (EE%) (solid line) vs loading (wt/wt%) (dotted line) for c
PLGA 50:50, d PLGA 75:25 and e PLGA 85:15. Results represent mean
± SD of triplicate measurements
Fig. 4 Incorporation of proteins within the PLGA nanoparticles. The effect
of the FRR on the physicochemical characteristics of the PLGA
nanoparticles incorporating OVA (TFR 10 mL/min): a particle size and
particle size distribution, b zeta potential and c encapsulation efficiency (%
of calculated concentration divided by initial amount added and multiplied
by FRR dilution factor; 0.2 mg/mL OVA initial concentration) vs loading
(wt/wt%). Results represent mean ± SD of at least triplicate measurements.
SEM micrographs of OVA-loaded d PLGA 50:50, e PLGA 75:25 and f
PLGA 85:15 nanoparticles formulated at FRR 1:1 and TFR 10mL/min after
purification
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achievable but this may be at the detriment to particle size if
more hydrophobic polymers are used (Fig. 6).
Previous studies have shown the change in the physico-
chemical characteristics of adjuvants systems upon
incorporation of proteins [36]. In general, encapsulation of
proteins within the nanoparticles provokes an increase in par-
ticle size. For example, Kissel et al. investigated the loading of
BSA onto block polymers at different concentrations and
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Fig. 6 The effect of the initial protein concentration loaded on the
physicochemical characteristics of the PLGA nanoparticles produced
using microfluidics at FRR 1:1 and TFR 10 mL/min: a particle size
(bars) and PDI (dots), b encapsulation efficiency (EE%) and c loading
(wt/wt%) for PLGA 50:50, PLGA 75:25 and PLGA 85:15. Results rep-
resent mean ± SD of triplicate measurements
Table 1 Effect of the type of protein loaded on the physicochemical
characteristics (particle size, PDI and zeta potential (ZP)) of the PLGA
nanoparticles produced using microfluidics at FRR 1:1 and TFR 10 mL/
min. Encapsulation efficiency was calculated as percentage of the
calculated concentration divided by the theoretical concentration and
loading capacity was calculated as the percentage of the mass of the
loaded protein divided by the mass of the whole nanoparticle. Results
represent mean ± SD of triplicate measurements
Particle size (nm) ± SD PDI ± SD ZP (mV) ± SD EE (%) ± SD % wt/wt ± SD
Ovalbumin (OVA)
PLGA 50:50 135 ± 9 0.23 ± 0.06 − 32 ± 5 21 ± 6 1.5 ± 0.4
PLGA 75:25 297 ± 12 0.28 ± 0.05 − 51 ± 3 35 ± 1 2.1 ± 0.1
PLGA 85:15 608 ± 36 0.3 ± 0.07 − 47 ± 2 36 ± 6 3.0 ± 0.5
Bovine serum albumin (BSA)
PLGA 50:50 138 ± 6 0.11 ± 0.02 − 38 ± 2 25 ± 4 1.8 ± 0.3
PLGA 75:25 239 ± 9 0.26 ± 0.02 − 54 ± 2 31 ± 7 1.8 ± 0.4
PLGA 85:15 613 ± 72 0.35 ± 0.06 − 46 ± 2 23 ± 2 1.9 ± 0.2
Hybrid 56 (H56)
PLGA 50:50 151 ± 6 0.24 ± 0.02 − 33 ± 2 7 ± 0.3 0.5 ± 0.02
PLGA 75:25 178 ± 3 0.13 ± 0.02 − 48 ± 2 35 ± 5 2.1 ± 0.3
PLGA 85:15 270 ± 11 0.16 ± 0.01 − 44 ± 2 38 ± 2 3.1 ± 0.2
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showed that increasing BSA concentration produced an in-
creased in the polymer microparticle size [37]. Yet, other stud-
ies have shown that incorporation of protein does not affect
the physicochemical characteristics of the particles. For exam-
ple, Azizi et al. produced BSA loaded PLGA 50:50 nanopar-
ticles using different BSA concentrations (from 0.01 to 1%
w/v) and the particle size of the nanoparticles did not change
upon increasing the protein concentration [38].
Varying the protein incorporated
within the nanoparticles
To consider the impact of protein choice on nanoparticle for-
mulation using microfluidics, different proteins were loaded at
TFR of 10 mL/min and FRR 1:1. The selected antigens were
as follows: BSA due to its larger molecular weight (Mw
66.5 kDa) and the TB vaccine candidate H56 (Mw
48.3 kDa). Protein loading was measured via HPLC. Table 1
outlines the physicochemical characteristics of the PLGA co-
polymers encapsulating these proteins at an initial protein con-
centration of 0.5 mg/mL (final concentration 0.25 mg/mL
when produced at FRR 1:1). The results in Table 1 demon-
strate that the type of protein loaded impacts on both the EE%
and the physicochemical characteristics of the nanoparticles.
With the PLGA 50:50 nanoparticles, the loading of the differ-
ent proteins had no notable effect on particle size with parti-
cles being 135–150 nm in size (Table 1). Therefore, both the
polymer adopted in the formulation and the protein being
incorporated have to be considered as both impact on the
attributes of the nanoparticles. Overall, the body of literature
confirms that the use of PLGA of higher hydrophobic content
promotes higher protein loading, which we hypothesise,
might be the result of the hydrophobic polymers rapidly ag-
gregating to form nanoparticles and thus capturing higher
amounts of proteins. Indeed similar results have been shown
by Koppolu et al. when loading different molecular weight
proteins (insulin, OVA, BSA and concanavalin A) into chito-
san based delivery systems [39]. The smallest molecular
weight (insulin 6 kDa) resulted in near 100% EE whereas
66.5 kDa BSA resulted in 56% EE. OVA and H56 have sim-
ilar molecular weights, and therefore, no significant differ-
ences were observed in their loading.
Conclusions
Through these studies, we have identified the critical process
parameters in the microfluidic production of PLGA nanopar-
ticles and outlined suggested process parameters that can be
adopted for their scale-independent microfluidic manufactur-
ing. By this method, proteins/antigens or peptides can be load-
ed in a single step into polymeric nanoparticles. Furthermore,
the use of surfactants was deemed unnecessary using this
production method. The formulation screening generated in
this study can be applied to the encapsulation of proteins and
antigens into PLGA nanoparticles, thus giving a scalable pro-
duction pathway from laboratory tools to patient therapies.
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